Modelling hepatitis C transmission over a social network of injecting drug users

Journal of Theoretical Biology

Volumn 297, Issue , 2012, Pages 73-87

  Rolls, D A ^a   Daraganova, G ^a   Sacks Davis, R ^b   Hellard, M ^b   Jenkinson, R ^b   McBryde, E ^a   Pattison, P E ^a   Robins, G L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BURNET INSTITUTE   (Australia)

Author keywords

Agent based; Computer simulation; Doubly stochastic; Importing; Spontaneous clearance

Indexed keywords

COMPUTER SIMULATION; DISEASE TRANSMISSION; DRUG PRESCRIBING; DRUG USER; HEPATITIS; NUMERICAL MODEL; SOCIAL NETWORK; STOCHASTICITY;

ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG ABUSE; HEPATITIS C; INCIDENCE; INFECTION RATE; PRIORITY JOURNAL; PROBABILITY; PROTECTION; RISK REDUCTION; SOCIAL NETWORK; VIRUS TRANSMISSION;

HEPATITIS C; HUMANS; MODELS, BIOLOGICAL; NEEDLE SHARING; RECURRENCE; RISK ASSESSMENT; SOCIAL SUPPORT; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; VICTORIA;

AUSTRALIA; MELBOURNE; VICTORIA [AUSTRALIA];

HEPATITIS C VIRUS;

EID: 84855275541     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.12.008     Document Type: Article

References (43)

1. Aitken C., Lewis J., Tracy S., Spelman R., Bowden D.S., Bharadwaj M., Drummer H., Hellard M. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008, 48:1746-1752.
2. Aitken C., McCaw R.F., Bowden D., Tracy S., Kelsall J., Higgs P., Kerger M., Nguyen H., Crofts J. Molecular epidemiology of hepatitis C virus in a social network of injection drug users. J. Infect. Dis. 2004, 190:1586-1596.
3. Anderson R., May R. Infectious Diseases of Humans 1991, Oxford University Press, London.
4. Barabási A.L., Albert R. Emergence of scaling in random networks. Science 1999, 286:509-512.
5. Brewer D.D., Hagan H., Sullivan D.G., Muth S.Q., Hough E.S., Feuerborn N.A., Gretch D.R. Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors. J. Infect. Dis. 2006, 194:764-772.
6. Cãruntu F., Benea L. Acute hepatitis C virus infection: diagnosis, pathogenesis, treatment. J. Gastrointest. Liver Dis. 2006, 15:249-256.
7. De P., Cox J., Boivin J., Platt R., Jolly A. Rethinking approaches to risk reduction for injection drug users: differences in drug type affect risk for HIV and hepatitis C virus infection through drug-injecting networks. J. Acquir. Immune. Defic. Syndr. 2007, 46:355-361.
8. De P., Roy E., Boivin J.F., Cox J., Morissette C. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. J. Viral Hepat. 2008, 15:279-292.
9. Esposito N., Rossi C. A nested-epidemic model for the spread of hepatitis C among injecting drug users. Math. Biosci. 2004, 188:29-45.
10. Gaver D.P. Random hazard in reliability problems. Technometrics 1963, 5:211-226.
11. Grandell J. Doubly stochastic Poisson processes. Lecture Notes in Mathematics 1976, vol. 529. Springer-Verlag, Berlin.
12. Hahn J.A., Wylie D., Dill J., Sanchez M.S., Lloyd-Smith J.O., Page-Shafer K., Getz W.M. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 2009, 1:47-57.
13. Hofer H., Watkins-Riedel T., Janata O., Penner E., Holzmann H., Steindl-Munda P., Gangl A., Ferenci P. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of viral load. Hepatology 2003, 37:60-64.
14. Hutchinson S., Bird S., Taylor A., Goldberg D. Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. Int. J. Drugs Policy 2006, 17:211-221.
15. Iversen, J., Topp, L., Maher, L., 2007. Australian NSP Survey National Data Report 2002-2006. National Centre in HIV Epidemiology and Clinical Research.
16. Kretzschmar M., Wiessing L. New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users. AIDS 2008, 22:1527-1537.
17. Krivitsky, P., Handcock, M., 2010. A separable model for dynamic networks. http://ArXiv:1011.1937v1.
18. Kwon J., Iversen J., Maher L., Law M., Wilson D. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J. Acquir. Immune. Defic. Syndr. 2009, 51.
19. Maher L., Jalaludin B., Chant K.G., Jayasuriya R., Sladden T., Kaldor J.M., Sargent P.L. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006, 101:1499-1508.
20. Mangia A., Santoro R., Minerva N., Ricci G., Carretta V., Persico M., Vinelli F., Scotto G., Bacca D., Annese M., Romano M., Zechini F., Sogari F., Spirito F., Andriulli A. Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 weeks in HCV Genotype 2 or 3. N. Engl. J. Med. 2005, 552:2609-2617.
21. Mather D., Crofts N. A computer model of the spread of hepatitis C virus among injecting drug users. Eur. J. Epidemiol. 1999, 15:5-10.
22. Meeker W.Q., Escobar L.A. Statistical methods for reliability data. Wiley Series in Probability and Statistics. Applied Probability and Statistics 1998, Wiley, New York.
23. Micallef J.M., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I., Kaldor J.M., White P.A., Dore G.J. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J. Viral Hepat. 2007, 14:413-418.
24. Miller M., Hellard M., Bowden S., Bharadwaj M., Aitken C. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J. Infect. 2009, 58:375-382.
25. Moneim I., Mosa G. Stochastic model for the spread of the hepatitis C virus with different types of virus genome. Aust. J. Basic Appl. Sci. 2009, 3:1253-1265.
26. Morris M. Network Epidemiology: A Handbook for Survey Design and Data Collection 2004, Oxford University Press.
27. Murray J.M., Law M.G., Gao Z., Kaldor J.M. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int. J. Epidemiol. 2003, 32:708-714.
28. NCHECR, 2006. Hepatitis C Virus Projections Working Group: estimates and projections of the hepatitis C virus epidemic in Australia 2006. National Centre in HIV Epidemiology and Clinical Research.
29. NCHECR, 2009. Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia. National Centre in HIV Epidemiology and Clinical Research.
30. Pollack H.A. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Med. Decis. Making 2001, 21:357-367.
31. Robins G., Pattison P., Kalish Y., Lusher D. An introduction to exponential random graph (p*) models for social networks. Soc. Networks 2007, 29:173-191.
32. Sacks-Davis, R., Daraganova, G., Aitken, C., Higgs, P., Tracy, L., Bowden, D., Robins, G., Pattison, P., Grebely, J., Barry, A., Hellard, M., 2011. Molecular epidemiology of hepatitis C in a social network of young people who inject drugs, 46th Annual Meeting of the European Association for the Study of the Liver (EASL), Berlin.
33. Salomon J.A., Weinstein M.C., Hammitt J.K., Goldie S.J. Empirically calibrated model of hepatitis C virus infection in the United States. Am. J. Epidemiol. 2002, 156:761-773.
34. Snijders T., Pattison P., Robins G., Handcock M. New specifications for exponential random graph models. Sociol. Methodol. 2006, 36:99-153.
35. Snijders T., Steglich C., van de Bunt G. Introduction to actor-based models for network dynamics. Soc. Networks 2010, 32:44-60.
36. Thein H., Yi Q., Dore G., Krahn M. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008, 48:418-431.
37. Vickerman P., Hickman M., Judd A. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. Int. J. Epidemiol. 2007, 36:396-405.
38. Vickerman P., Platt L., Hawkes S. Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi a low HCV prevalence setting in Pakistan. Sex. Transm. Infect. 2009, 85:ii23-ii30.
39. Watanabe H., Saito T., Shinzawa H., Okumoto K., Hattori E., Adachi T., Takeda T., Sugahara K., Ito J., Saito K., Togashi H., Suzuki R., Hayashi M., Miyamura T., Matsuura Y., Kawata S. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: a population-based cohort study. J. Med. Virol. 2003, 71:56-61.
40. Watts D.J., Strogatz S.H. Collective dynamics of "small-world" networks. Nature 1998, 393:440-442.
41. Welch D., Bansal S., Hunter D.R. Statistical inference to advance network models in epidemiology. Epidemics 2011, 3:38-45.
42. Wylie J., Shah L., Jolly A. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health 2006, 6:229.
43. Yu M., Dai C., Huang J., Chiu C., Yang Y., Hou N., Lee L., Hsieh M., Lin Z., Chen S., Hsieh M., Wang L., Chang W., Chuang W. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008, 47:1884-1893.